SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
(2020) In Molecular and Cellular Oncology 7(6).- Abstract
The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical... (More)
The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical debulking surgery overall and progression-free survival were shorter for patients with SOX2 positive tumors (mean 26 vs. 39 months, log-rank test: p = .0076, and mean 14 vs. 19 months, p = .055, respectively). Knockdown of SOX2 in cell lines did not affect growth inhibition following chemotherapy treatment. Our results show that SOX2 has a strong prognostic potential among HGSOC patients with residual tumor tissue after debulking surgery and suggest that SOX2 expressing cells remaining after non-radical debulking surgery may constitute a subpopulation of cancer stem cells with greater tumor-initiating potential.
(Less)
- author
- Bååth, Maria LU ; Westbom-Fremer, Sofia LU ; Martin de la Fuente, Laura LU ; Ebbesson, Anna LU ; Davis, Juliette ; Malander, Susanne LU ; Måsbäck, Anna LU ; Kannisto, Päivi LU and Hedenfalk, Ingrid LU
- organization
- publishing date
- 2020-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cancer stem cells, high-grade serous ovarian cancer, radical surgery, SOX2, survival
- in
- Molecular and Cellular Oncology
- volume
- 7
- issue
- 6
- article number
- 1805094
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:33235906
- scopus:85090303239
- ISSN
- 2372-3556
- DOI
- 10.1080/23723556.2020.1805094
- language
- English
- LU publication?
- yes
- id
- 22813360-b6ab-4a19-82b7-081ec74de802
- date added to LUP
- 2020-09-15 12:29:47
- date last changed
- 2024-08-22 03:34:40
@article{22813360-b6ab-4a19-82b7-081ec74de802, abstract = {{<p>The transcription factor SOX2 is a well-established and important stem cell marker. Its role in cancer biology remains unclear, but it has been proposed to also be a marker of cancer stem cells. We investigated the role of SOX2 protein expression in women with high-grade serous ovarian cancer (HGSOC) to determine its potential prognostic and treatment predictive value. We constructed a tissue microarray of 130 advanced stage HGSOC tumors with an average of 6 cores each, stained for SOX2 protein expression and evaluated survival outcomes. We also treated two HGSOC cell lines with carboplatin and paclitaxel and measured SOX2 expression by RT-PCR and immunoblotting at different doses and time-points. Among patients with non-radical debulking surgery overall and progression-free survival were shorter for patients with SOX2 positive tumors (mean 26 vs. 39 months, log-rank test: p = .0076, and mean 14 vs. 19 months, p = .055, respectively). Knockdown of SOX2 in cell lines did not affect growth inhibition following chemotherapy treatment. Our results show that SOX2 has a strong prognostic potential among HGSOC patients with residual tumor tissue after debulking surgery and suggest that SOX2 expressing cells remaining after non-radical debulking surgery may constitute a subpopulation of cancer stem cells with greater tumor-initiating potential.</p>}}, author = {{Bååth, Maria and Westbom-Fremer, Sofia and Martin de la Fuente, Laura and Ebbesson, Anna and Davis, Juliette and Malander, Susanne and Måsbäck, Anna and Kannisto, Päivi and Hedenfalk, Ingrid}}, issn = {{2372-3556}}, keywords = {{Cancer stem cells; high-grade serous ovarian cancer; radical surgery; SOX2; survival}}, language = {{eng}}, number = {{6}}, publisher = {{Taylor & Francis}}, series = {{Molecular and Cellular Oncology}}, title = {{SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery}}, url = {{http://dx.doi.org/10.1080/23723556.2020.1805094}}, doi = {{10.1080/23723556.2020.1805094}}, volume = {{7}}, year = {{2020}}, }